Compare Dishman Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs GSK PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA GSK PHARMA DISHMAN PHARMA/
GSK PHARMA
 
P/E (TTM) x 25.1 -79.1 - View Chart
P/BV x 3.3 11.8 28.4% View Chart
Dividend Yield % 0.7 1.3 49.5%  

Financials

 DISHMAN PHARMA   GSK PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
GSK PHARMA
Mar-19
DISHMAN PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs3743,595 10.4%   
Low Rs1291,253 10.3%   
Sales per share (Unadj.) Rs197.8184.7 107.1%  
Earnings per share (Unadj.) Rs21.226.3 80.7%  
Cash flow per share (Unadj.) Rs34.729.2 119.1%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.80.8 96.3%  
Book value per share (Unadj.) Rs179.9126.3 142.4%  
Shares outstanding (eoy) m80.69169.40 47.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.313.1 9.7%   
Avg P/E ratio x11.992.2 12.9%  
P/CF ratio (eoy) x7.283.1 8.7%  
Price / Book Value ratio x1.419.2 7.3%  
Dividend payout %9.476.1 12.4%   
Avg Mkt Cap Rs m20,306410,626 4.9%   
No. of employees `0000.85.0 16.7%   
Total wages/salary Rs m5,3555,372 99.7%   
Avg. sales/employee Rs Th19,252.76,306.7 305.3%   
Avg. wages/employee Rs Th6,459.51,083.1 596.4%   
Avg. net profit/employee Rs Th2,064.1898.0 229.9%   
INCOME DATA
Net Sales Rs m15,96131,281 51.0%  
Other income Rs m2651,023 25.9%   
Total revenues Rs m16,22632,304 50.2%   
Gross profit Rs m4,1036,009 68.3%  
Depreciation Rs m1,091486 224.4%   
Interest Rs m9446 15,740.0%   
Profit before tax Rs m2,3346,540 35.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m6242,373 26.3%   
Profit after tax Rs m1,7114,454 38.4%  
Gross profit margin %25.719.2 133.8%  
Effective tax rate %26.736.3 73.6%   
Net profit margin %10.714.2 75.3%  
BALANCE SHEET DATA
Current assets Rs m11,01820,061 54.9%   
Current liabilities Rs m9,51714,543 65.4%   
Net working cap to sales %9.417.6 53.3%  
Current ratio x1.21.4 83.9%  
Inventory Days Days11057 194.6%  
Debtors Days Days3514 247.8%  
Net fixed assets Rs m16,30414,343 113.7%   
Share capital Rs m1611,694 9.5%   
"Free" reserves Rs m12,90719,704 65.5%   
Net worth Rs m14,51621,398 67.8%   
Long term debt Rs m4,1892 209,470.0%   
Total assets Rs m29,80539,113 76.2%  
Interest coverage x3.51,091.0 0.3%   
Debt to equity ratio x0.30 308,794.0%  
Sales to assets ratio x0.50.8 67.0%   
Return on assets %8.911.4 78.1%  
Return on equity %11.820.8 56.6%  
Return on capital %17.531.9 54.9%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,952534 927.2%   
Fx outflow Rs m6977,091 9.8%   
Net fx Rs m4,255-6,557 -64.9%   
CASH FLOW
From Operations Rs m2,7863,994 69.8%  
From Investments Rs m-1,529-1,433 106.7%  
From Financial Activity Rs m-941-3,584 26.3%  
Net Cashflow Rs m316-1,023 -30.9%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 3.7 10.2 36.3%  
FIIs % 12.7 23.8 53.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 15.4 143.5%  
Shareholders   46,261 102,036 45.3%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   PIRAMAL ENTERPRISES  ABBOTT INDIA  PANACEA BIOTECH  DR. REDDYS LAB  NOVARTIS  

Compare DISHMAN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS